1. Engineering a targeted and safe bone anabolic gene therapy to treat osteoporosis in alveolar bone loss.
- Author
-
Lin C, Yang YS, Ma H, Chen Z, Chen D, John AA, Xie J, Gao G, and Shim JH
- Subjects
- Animals, Mice, Humans, Genetic Vectors administration & dosage, Genetic Vectors genetics, MicroRNAs genetics, Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing metabolism, Female, Osteoblasts metabolism, Wnt Signaling Pathway, Genetic Therapy methods, Osteoporosis therapy, Osteoporosis genetics, Osteoporosis metabolism, Osteoporosis etiology, Dependovirus genetics, Alveolar Bone Loss therapy, Alveolar Bone Loss etiology, Alveolar Bone Loss genetics, Alveolar Bone Loss metabolism, Disease Models, Animal
- Abstract
Alveolar bone loss in elderly populations is highly prevalent and increases the risk of tooth loss, gum disease susceptibility, and facial deformity. Unfortunately, there are very limited treatment options available. Here, we developed a bone-targeted gene therapy that reverses alveolar bone loss in patients with osteoporosis by targeting the adaptor protein Schnurri-3 (SHN3). SHN3 is a promising therapeutic target for alveolar bone regeneration, because SHN3 expression is elevated in the mandible tissues of humans and mice with osteoporosis while deletion of SHN3 in mice greatly increases alveolar bone and tooth dentin mass. We used a bone-targeted recombinant adeno-associated virus (rAAV) carrying an artificial microRNA (miRNA) that silences SHN3 expression to restore alveolar bone loss in mouse models of both postmenopausal and senile osteoporosis by enhancing WNT signaling and osteoblast function. In addition, rAAV-mediated silencing of SHN3 enhanced bone formation and collagen production of human skeletal organoids in xenograft mice. Finally, rAAV expression in the mandible was tightly controlled via liver- and heart-specific miRNA-mediated repression or via a vibration-inducible mechanism. Collectively, our results demonstrate that AAV-based bone anabolic gene therapy is a promising strategy to treat alveolar bone loss in osteoporosis., Competing Interests: Declaration of interests G.G. and J.H.S. have submitted a patent application concerning the methodology described in this study. G.G. and J.H.S. are scientific co-founders of AAVAA Therapeutics and hold equity in this company. G.G. is also a scientific co-founder of Voyager Therapeutics, Adrenas Therapeutics, and Aspa Therapeutics, and holds equity in these companies. G.G. is an inventor on patents with potential royalties licensed to Voyager Therapeutics, Adrenas Therapeutics, Aspa Therapeutics, and other biopharmaceutical companies., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF